论文部分内容阅读
目的探讨CRABPII和E-FABP在乳腺浸润性导管癌中的表达差异及与临床病理特征和预后的关系。方法采用免疫组化SP法检测152例乳腺浸润性导管癌中CRABPII和E-FABP的表达。结果 CRABPII和EFABP在乳腺浸润性导管癌中的表达存在差异(P<0.05),E-FABP 72.4%的阳性率高于CRABPII的33.6%。CRABPII和E-FABP的差异性表达与肿瘤有/无转移、TNM分期有关(P<0.05),与患者预后无关(P>0.05)。结论在乳腺浸润性导管癌中,E-FABP在肿瘤中的阳性表达率较CRABPII高,伴有癌转移、TNM分期晚的肿瘤阳性率更高。调节肿瘤细胞中CRABPII/E-FABP的比例有望成为乳腺癌个性化靶向治疗研究的新方向。
Objective To investigate the differential expression of CRABPII and E-FABP in invasive ductal carcinoma of the breast and its relationship with clinicopathological features and prognosis. Methods Immunohistochemical SP method was used to detect the expression of CRABPII and E-FABP in 152 cases of invasive ductal carcinoma of the breast. Results The expression of CRABPII and EFABP in invasive ductal carcinoma of the breast was significantly different (P <0.05). The positive rate of E-FABP in 72.4% was higher than that of CRABPII in 33.6%. The differential expression of CRABPII and E-FABP was correlated with the presence / absence of metastasis and TNM staging (P <0.05), but not with the prognosis of patients (P> 0.05). Conclusions In breast invasive ductal carcinoma, the positive expression rate of E-FABP in tumor is higher than that of CRABPII, with the metastasis of cancer, and the positive rate of TNM staging is higher. Regulating the proportion of CRABPII / E-FABP in tumor cells is expected to become a new direction for personalized targeted therapy of breast cancer.